Eupatilin/jaceosidin - Dong-A ST
Alternative Names: Jaceosidin/eupatilin; StillenLatest Information Update: 07 Oct 2015
At a glance
- Originator Dong-A Pharmaceutical
- Developer Dong-A ST
- Class Cytoprotectives; Phytotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Gastric ulcer; Gastritis
- No development reported Gastro-oesophageal reflux
Most Recent Events
- 07 Oct 2015 No recent reports of development identified - Preclinical for Gastro-oesophageal reflux in South Korea (PO)
- 31 Oct 2007 Data presented at the 15th United European Gastroenterology Week (UEGW-2007) added to the adverse events and Peptic Ulcer Disease therapeutic trials sections
- 01 Aug 2003 Data presented at the Digestive Disease Week - 2003 (DDW-2003) have been added to the Peptic ulcer disease pharmacodynamics section